DP
RIGL icon

Diadema Partners’s Rigel Pharmaceuticals RIGL Stock Holding History

Diadema Partners’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$893K Buy
+22,816
New +$704K 0.11% 108
2026
Q1 		– Sell
-30,000
Closed -$1.28M – 195
2025
Q4 		$1.28M Buy
+30,000
New +$1.13M 0.22% 84

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Diadema Partners's RIGL Position: Q2 2026 in Review

Diadema Partners opened a new position in Rigel Pharmaceuticals (RIGL) in Q2 2026: 22,816 shares worth $893K. The stake represents 0.11% of the portfolio and ranks #108 among its holdings. This is a return to the name: Diadema Partners previously reported a position in RIGL as recently as Q4 2025.

Diadema Partners first reported a position in RIGL in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.28M in Q4 2025. 156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Diadema Partners held 22,816 shares of Rigel Pharmaceuticals worth $893K as of Q2 2026.
  • Rigel Pharmaceuticals was a new Diadema Partners position in Q2 2026.
  • Rigel Pharmaceuticals made up 0.11% of Diadema Partners's portfolio in Q2 2026, its #108 holding.
  • Diadema Partners first reported a position in Rigel Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Diadema Partners's Rigel Pharmaceuticals position peaked at $1.28M in Q4 2025.
  • 156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.